News - AMAG Pharmaceuticals, Incyte

Filter

Popular Filters

FDA cites insufficient information in response to AMAG’s Feraheme application

FDA cites insufficient information in response to AMAG’s Feraheme application

23-01-2014

US drug company AMAG Pharmaceuticals (Nasdaq: AMAG) has received a complete response letter from the…

AMAG PharmaceuticalsFerahemeHematologyNephrology and HepatologyPharmaceuticalRegulationUSA

Herve Hoppenot quits Novartis to join Incyte

Herve Hoppenot quits Novartis to join Incyte

13-01-2014

Swiss drug major Novartis said on Sunday (January 12), that Herve Hoppenot, president of Novartis Oncology,…

BoardroomIncyteManagementNovartisPharmaceutical

Incyte soars on positive mid-stage ruxolitinib trial results

22-08-2013

Shares of US drug developer Incyte Corp (Nasdaq: INCY) leapt 21% to $32.55 in premarket trading yesterday…

IncyteJakafiOncologyPharmaceuticalResearchruxolitinib

Licensing deals between Xenon and Isis for XEN701, and Access and AMAG for MuGard

10-06-2013

USA-based Isis Pharmaceuticals (Nasdaq: ISIS) revealed that privately-held Canadian firm Xenon Pharmaceuticals…

Access PharmaceuticalsAMAG PharmaceuticalsIsis PharmaceuticalsLicensingMuGardNephrology and HepatologyOncologyPharmaceuticalXEN701Xenon Pharmaceuticals

First myelofibrosis drug, Novartis' Jakavi, approved in Europe

29-08-2012

Swiss drug major Novartis (NOVN: VX) received approval yesterday from the European Commission for Jakavi…

EuropeIncyteJakafiJakaviNovartisOncologyPharmaceuticalRare diseasesRegulation

Allos looks to complete merger with AMAG, as third party bows out

11-10-2011

Allos Therapeutics (Nasdaq: ALTH) says that it continues to work with fellow USA-based AMAG Pharmaceuticals…

Allos TherapeuticsAMAG PharmaceuticalsMergers & AcquisitionsPharmaceutical

US FDA grants priority review as it accepts Incyte ruxolitinib NDA for myelofibrosis

04-08-2011

The US Food and Drug Administration has accepted for filing the New Drug Application (NDA) for drug developer…

IncyteNorth AmericaNovartisOncologyPharmaceuticalRegulationruxolitinib

US deal for Vectura; takeover bid for AMAG

03-08-2011

There was good news this morning from Vectura Group (LSE: VEC), a UK-based inhalation product development…

Allos TherapeuticsAMAG PharmaceuticalsLicensingMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryVectura

AMAG Pharma and Allos Thera to merge in $686 million stock deal; Express Scripts to buy Medco

21-07-2011

US drugmakers AMAG Pharmaceuticals (Nasdaq: AMAG) and Allos Therapeutics (Nasdaq: ALTH) entered into…

Allos TherapeuticsAMAG PharmaceuticalsBiotechnologyMergers & AcquisitionsPharmaceutical

Back to top